129 related articles for article (PubMed ID: 27249725)
1. The Past, Present, and Future of Pancreatic Cancer Clinical Trials.
Matrisian LM; Berlin JD
Am Soc Clin Oncol Educ Book; 2016; 35():e205-15. PubMed ID: 27249725
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Mosquera C; Maglic D; Zervos EE
Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
[TBL] [Abstract][Full Text] [Related]
3. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
4. Molecular landscape of pancreatic cancer: implications for current clinical trials.
Heestand GM; Kurzrock R
Oncotarget; 2015 Mar; 6(7):4553-61. PubMed ID: 25714017
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.
Schlick K; Kiem D; Greil R
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680101
[TBL] [Abstract][Full Text] [Related]
6. Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer.
Baines AT; Martin PM; Rorie CJ
Prog Mol Biol Transl Sci; 2016; 144():277-320. PubMed ID: 27865460
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer: the role of molecular markers in diagnosis and management.
Lowery MA; O'Reilly EM
Clin Adv Hematol Oncol; 2011 Dec; 9(12):900-8. PubMed ID: 22252658
[TBL] [Abstract][Full Text] [Related]
8. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer.
Cao D; Song Q; Li J; Jiang Y; Wang Z; Lu S
Expert Rev Mol Med; 2021 Dec; 23():e21. PubMed ID: 34906271
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer clinical trials and accrual in the United States.
Hoos WA; James PM; Rahib L; Talley AW; Fleshman JM; Matrisian LM
J Clin Oncol; 2013 Sep; 31(27):3432-8. PubMed ID: 23960185
[TBL] [Abstract][Full Text] [Related]
10. HIFU for Palliative Treatment of Pancreatic Cancer.
Khokhlova TD; Hwang JH
Adv Exp Med Biol; 2016; 880():83-95. PubMed ID: 26486333
[TBL] [Abstract][Full Text] [Related]
11. Gene and cell therapy for pancreatic cancer.
Singh HM; Ungerechts G; Tsimberidou AM
Expert Opin Biol Ther; 2015 Apr; 15(4):505-16. PubMed ID: 25582170
[TBL] [Abstract][Full Text] [Related]
12. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma.
Yu IS; Cheung WY
Can J Gastroenterol Hepatol; 2018; 2018():1863535. PubMed ID: 29623263
[TBL] [Abstract][Full Text] [Related]
13. Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer.
Rocha FG
Ann Surg Oncol; 2021 Mar; 28(3):1400-1406. PubMed ID: 33386541
[TBL] [Abstract][Full Text] [Related]
14. Advances in Molecular Pathology and Treatment of Periampullary Cancers.
Chandrasegaram MD; Chen JW; Price TJ; Zalcberg J; Sjoquist K; Merrett ND
Pancreas; 2016 Jan; 45(1):32-9. PubMed ID: 26348463
[TBL] [Abstract][Full Text] [Related]
15. Promising new therapies in advanced pancreatic adenocarcinomas.
Kundranda M; Kachaamy T
Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
[TBL] [Abstract][Full Text] [Related]
16. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
17. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
19. Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness.
Di Caro G; Castino GF; Bergomas F; Cortese N; Chiriva-Internati M; Grizzi F; Marchesi F
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1219-28. PubMed ID: 25222571
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
